Poll Results Spotlight Key Lung Cancer Abstracts Driving Anticipation Ahead of ESMO 2025

In the lead-up to the 2025 ESMO Congress, anticipation is mounting around several late-breaking abstracts in lung cancer expected to shape evolving standards of care.

To capture expert perspectives, OncLive® conducted polls on both X and LinkedIn to identify which lung cancer abstracts and topics were generating the most interest ahead of the meeting.

Poll Results Recap

On X, interest in the phase 2 NorthStar trial (NCT03410043) of osimertinib (Tagrisso) plus local consolidative therapy in EGFR-mutated non–small cell lung cancer (NSCLC) led the poll with 34.6% of 26 total votes, followed by interest in the phase 1 Beamion LUNG 1 trial (NCT04886804) of zongertinib (Hernexeos; formerly BI 1810631) in HER2-mutant NSCLC (26.9%). Interest was tied at 19.2% each for the phase 3 SKYSCRAPER-03 trial (NCT04513925) of atezolizumab (Tecentriq) plus tiragolumab (MTIG7192A) in locally advanced NSCLC and the phase 2 MDT-BRIDGE trial (NCT05925530) of perioperative durvalumab (Imfinzi)–based treatment regimens in NSCLC.

On LinkedIn, enthusiasm was more evenly split, with the NorthStar trial and SKYSCRAPER-03 each drawing 36% of 14 total votes. Interest in Beamion LUNG 1 followed at 21%, and 7% of voters were interested in MDT-BRIDGE.

When asked which topics in lung cancer experts were most interested in during ESMO 2025, actionable alterations overwhelmingly led on both platforms:

• On X, 75% of 4 total voters selected actionable alterations, followed by 25% of voters who selected defining resectability; no votes were cast for antibody-drug conjugates (ADCs) or trends in small cell lung cancer (SCLC).
• On LinkedIn, interest in actionable alterations again led at 46% of 43 total voters, followed by ADCs at 27%, trends in SCLC at 24%, and defining resectability at 2%.

Read on for more information on the trials.

LBA72: NorthStar: A Phase II Randomized Study of Osimertinib (OSI) With or Without Local Consolidative Therapy (LCT) for Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Presentation time: Fri, October 17, 2025, 4:00-4:10pm CET

This randomized study is evaluating osimertinib with surgery and/or radiation therapy vs osimertinib alone in patients with stage IIIB to IV NSCLC harboring EGFR mutations.1 The primary end point of the trial is progression-free survival (PFS), with overall survival (OS) as a key secondary end point.

LBA69: Phase 3, Open-Label, Randomised Study of Atezolizumab (Atezo) + Tiragolumab (Tira) vs Durvalumab (Durva) in Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Concurrent Chemoradiation (cCRT)

Presentation time: Sat, October 18, 2025, 9:25-9:35am CET

SKYSCRAPER-03 is an open-label, randomized study evaluating atezolizumab plus tiragolumab vs durvalumab in patients with locally advanced, unresectable stage III NSCLC who have not progressed following at least 2 cycles of concurrent platinum-based chemoradiotherapy.2 Patients were randomly assigned to receive either atezolizumab at 1680 mg plus tiragolumab at 840 mg every 4 weeks for up to 13 cycles (arm A) or durvalumab administered either every 2 weeks at 10 mg/kg or every 4 weeks at a fixed dose of 1500 mg (arm B). The primary end point is PFS, with OS as a key secondary end point.

Notably, previously reported data from the phase 3 SKYSCRAPER-01 trial (NCT04294810) showed no statistically significant PFS or OS benefit with tiragolumab plus atezolizumab vs atezolizumab alone in the first-line setting in patients with locally advanced, unresectable or metastatic, PD-L1–high NSCLC.3

LBA65: Neoadjuvant Durvalumab (D) + Chemotherapy (CT) Followed by Either Surgery (Sx) and Adjuvant D or CRT and Consolidation D in Patients (pts) With Resectable or Borderline Resectable Stage IIB–IIIB NSCLC: Interim Analysis (IA) of the Phase 2 MDT-BRIDGE Study

Presentation time: Sat, October 18, 2025, 9:15-9:25am CET

MDT-BRIDGE is a multicenter, single-arm study evaluating neoadjuvant durvalumab plus platinum-based chemotherapy followed by either surgery, then adjuvant durvalumab, or chemoradiotherapy plus consolidation durvalumab in patients with resectable or borderline resectable stage IIB to IIIB NSCLC.4 In neoadjuvant period A, all patients received 2 cycles of durvalumab combined with platinum-based chemotherapy every 3 weeks, after which resectability was assessed by a multidisciplinary team. In neoadjuvant period B, patients deemed resectable received 1 to 2 additional cycles of durvalumab plus chemotherapy before surgery, followed by surgery and adjuvant durvalumab every 4 weeks for up to 1 year or until disease progression or recurrence. Patients with unresectable tumors received 6 weekly cycles of chemoradiotherapy followed by consolidation durvalumab. The primary end point is resection rate. Secondary end points include pathologic complete response rate, OS, event-free survival, PFS, overall response rate, circulating tumor DNA clearance, and safety.

LBA74: Zongertinib as First-Line Treatment in Patients With Advanced HER2-Mutant NSCLC: Beamion LUNG 1

Presentation time: Fri, October 17, 2025, 4:35-4:45pm CET

Beamion LUNG 1 is an open-label, dose-escalation and expansion study evaluating zongertinib monotherapy in patients with advanced or metastatic solid tumors harboring HER2 aberrations, including NSCLC.5 In part 1, patients with solid tumors harboring HER2 alterations who had progressed on prior therapy were enrolled to establish the maximum tolerated dose of zongertinib, administered orally once or twice daily. In part 2, patients with NSCLC and confirmed HER2 mutations who were pretreated (cohorts 1, 3, 4, 5, 6, and 7) or treatment naive (cohorts 2, 4, and 8) received zongertinib at the recommended expansion dose to assess clinical activity, including tumor shrinkage and duration of response. Treatment continued until disease progression or unacceptable toxicity, with patients monitored regularly for safety, tumor response, and adverse effects.

Notably, data from previously treated patients enrolled in Beamion LUNG 1 supported the August 2025 FDA accelerated approval of zongertinib for the treatment of adult patients with unresectable or metastatic nonsquamous NSCLC with tumors harboring HER2 tyrosine kinase domain-activating mutations.6

References

1. Osimertinib, surgery, and radiation therapy in treating patients with stage IIIB or IV non-small cell lung cancer with EGFR mutations, NORTHSTAR study. ClinicalTrials.gov. Updated June 11, 2025. Accessed September 25, 2025. https://clinicaltrials.gov/study/NCT03410043
2. A study of atezolizumab and tiragolumab compared with durvalumab in participants with locally advanced, unresectable stage iii non-small cell lung cancer (NSCLC) (SKYSCRAPER-03). ClinicalTrials.gov. Updated September 9, 2025. Accessed September 26, 2025. https://clinicaltrials.gov/study/NCT04513925
3. Peters S, Herbst R, Horinouchi H, et al. SKYSCRAPER-01: a phase III, randomized trial of tiragolumab (tira) + atezolizumab (atezo) versus placebo (pbo) + atezo in patients (pts) with previously-untreated PD-L1-high, locally advanced unresectable/metastatic NSCLC. Presented at: 2025 AACR Annual Meeting; April 25-30, 2025; Chicago, IL. CT051.
4. Study to assess neoadjuvant durvalumab (D) and platinum-based chemotherapy (CT), followed by either surgery and adjuvant D or CRT and consolidation D, in resectable or borderline resectable stage IIB-IIIB NSCLC (MDT-BRIDGE) (MDT-BRIDGE). ClinicalTrials.gov. Updated August 21, 2025. Accessed September 25, 2025. https://www.clinicaltrials.gov/study/NCT05925530
5. Beamion LUNG 1: a study to test different doses of zongertinib in people with different types of advanced cancer (solid tumours with changes in the HER2 gene). ClinicalTrials.gov. Updated September 19, 2025. Accessed September 25, 2025. https://clinicaltrials.gov/study/NCT04886804
6. FDA grants accelerated approval to zongertinib for non-squamous NSCLC with HER2 TKD activating mutations. FDA. August 8, 2025. Accessed September 26, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zongertinib-non-squamous-nsclc-her2-tkd-activating-mutations